Filing Flows › Intellia Therapeutics (NTLA) › Q3 2025
Intellia Therapeutics (NTLA) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Intellia Therapeutics (NTLA) reported revenue of $13.8M for the third quarter 2025 (Q3 2025), +51% from a year earlier and -3% from the quarter before. Operating margin was -808.9%, net loss $101M (735.2% of revenue).
Intellia Therapeutics, Q3 2025: revenue $13.8M (+51% year over year), operating margin -808.9%, net loss $101M, operating cash flow −$76.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.8M | -3% | +51% |
| Operating profit | −$111M | — | — |
| Net earnings | −$101M | — | — |
| Operating cash flow | −$76.9M | — | — |
What changed
Revenue was $13.8M in Q3 2025, up 51% year over year and down 3% from the previous quarter.
Operating costs exceeded revenue by $111.5M, an operating margin of -808.9%. Total costs fell 19% while revenue rose 51%. The quarter ended with a net loss of $101.3M, wider than the previous quarter's $101.3M loss.
Operating cash flow was −$76.9M. Non-cash charges added back $2.4M of depreciation and amortization and $19.6M of share-based compensation. Capital expenditures of $29K exceeded it, leaving free cash flow of −$76.9M.
Questions
What was Intellia Therapeutics' revenue in the third quarter 2025?
Intellia Therapeutics (NTLA) reported revenue of $13.8M for the third quarter 2025 (Q3 2025), +51% from a year earlier and -3% from the quarter before.
Was Intellia Therapeutics profitable in the third quarter 2025?
Operating loss was $111M (-808.9% of revenue) and net loss $101M.